Sarepta Therapeutics' (SRPT) "Neutral" Rating Reiterated at Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "neutral" rating reissued by stock analysts at Cantor Fitzgerald in a research note issued on Monday, MarketBeat Ratings reports.

A number of other research analysts have also recently commented on the stock. BMO Capital Markets cut shares of Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $120.00 to $70.00 in a research report on Monday. Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research report on Wednesday, May 7th. Oppenheimer decreased their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 20th. Finally, The Goldman Sachs Group cut their target price on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $104.17.

Sarepta Therapeutics Trading Down 43.9%

Shares of SRPT traded down $15.88 during midday trading on Monday, reaching $20.30. The company had a trading volume of 34,801,086 shares, compared to its average volume of 1,943,258. The firm has a 50 day simple moving average of $46.25 and a 200-day simple moving average of $86.03. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market cap of $1.99 billion, a PE ratio of 16.21 and a beta of 0.61. Sarepta Therapeutics has a 1-year low of $18.33 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS. Research analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the stock. Capital International Investors grew its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the last quarter. Norges Bank acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $126,315,000. Assenagon Asset Management S.A. boosted its holdings in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after acquiring an additional 580,123 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after acquiring an additional 577,848 shares during the period. Finally, EcoR1 Capital LLC increased its stake in shares of Sarepta Therapeutics by 67.8% during the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after acquiring an additional 522,386 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.